Spero Therapeutics
SPRO
44 hedge funds and large institutions have $32.1M invested in Spero Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 10 closing their positions.
195% more capital invested
Capital invested by funds: $10.9M → $32.1M (+$21.3M)
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
16% more funds holding
Funds holding: 38 → 44 (+6)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
7.9% less ownership
Funds ownership: 27.71% → 19.82% (-7.9%)
68% less call options, than puts
Call options by funds: $447K | Put options by funds: $1.38M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$735K |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
+$344K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$269K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$226K |
| 5 |
ICM
Ionic Capital Management
New York
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$3.14M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.09M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$946K |
| 4 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$629K |
| 5 |
AVLSA
Atlas Venture Life Science Advisors
Cambridge,
Massachusetts
|
-$220K |
SPRO Hedge Fund Activity: Q2 2025 in Review
44 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q2 2025, worth a combined $32.1M — up 195% from $10.9M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new SPRO positions and 10 closed out — a net gain of 6 holders — while 9 added to existing stakes and 9 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $735K. The largest seller was Anson Funds Management, cutting an estimated $3.14M.
- 44 institutional investors held Spero Therapeutics (SPRO) as of Q2 2025, up from 38 in Q1 2025.
- Funds reported $32.1M of Spero Therapeutics stock for Q2 2025, up 195% quarter-over-quarter.
- 16 funds opened new Spero Therapeutics positions in Q2 2025 and 10 closed out, a net change of +6 holders.
- The largest Spero Therapeutics buyer in Q2 2025 was Schonfeld Strategic Advisors, an estimated $735K added.
- The largest Spero Therapeutics seller in Q2 2025 was Anson Funds Management, an estimated $3.14M sold.
Based on aggregated 13F filings for Q2 2025.